The Danish Cancer Registry holds information on all prostate cancers (PCa) cases, including diagnostic TNM. However, stratification according to contemporary risk classification is not possible because histopathological grading and prostate-specific antigen (PSA) level are not registered. The objective of the study was to report clinical characteristics and primary management of men diagnosed with PCa from a primary referral center in Denmark.
Records on all men diagnosed with PCa at the Department of Urology, Frederiksberg Hospital, 1 January 2007 - 31 December 2013, were reviewed. Clinical characteristics and primary treatment were recorded. The National Comprehensive Cancer Network risk group classification was used.
A total of 1934 men with a median age of 69 years (interquartile range 65-75) were diagnosed with PCa in the study period resulting in an incidence rate (World Standard Population) of 84/100 000. Overall, 18% were classified as low-risk, 34% as intermediate-risk, 23% as high-risk, 8% as very high-risk and 17% had metastatic disease at diagnosis. Among men age <65 years 70% had low- or intermediate-risk disease, while this was the case for 58% of men aged 65-75 and 22% of men aged >75. Metastatic disease was found in 11% of men <65 years, 17% of men 65-75 years and 23% of men >75 years. In total 73% of men with low-risk PCa were managed on watchful waiting or active surveillance. Curatively intended treatment was performed in 56% of men with intermediate-risk and 61% of men with high-risk PCa, while hormonal therapy was used in 90% of men with very high-risk and 98% of men with metastatic PCa.
In a population without systematic PSA testing we found a large proportion of patients presenting with advanced PCa at diagnosis. Elderly patients presented with more advanced disease. Curative treatment was primarily used in younger men with clinically localized PCa.
Acta oncologica (Stockholm, Sweden). 2016 Jun 22 [Epub ahead of print]
Frederik B Thomsen, Marta K Mikkelsen, Rikke B Hansen, Andrea H Krug, Anders Glenthøj, Pär Stattin, Klaus Brasso
a Department of Urology , Bispebjerg and Frederiksberg Hospital , Frederiksberg , Denmark ;, a Department of Urology , Bispebjerg and Frederiksberg Hospital , Frederiksberg , Denmark ;, a Department of Urology , Bispebjerg and Frederiksberg Hospital , Frederiksberg , Denmark ;, b Copenhagen Prostate Cancer Center, Department of Urology , Rigshospitalet, University of Copenhagen , Copenhagen , Denmark ;, c Department of Pathology , Rigshospitalet, University of Copenhagen , Copenhagen , Denmark ;, d Department of Surgical and Perioperative Sciences, Urology and Andrology , Umeå University Hospital , Umeå , Sweden ;, b Copenhagen Prostate Cancer Center, Department of Urology , Rigshospitalet, University of Copenhagen , Copenhagen , Denmark ;